Yiming Liu

Partner in Charge – Shanghai
Full contact info

Experience

Brii Biosciences Announces Agreements to Acquire VBI Vaccines’ IP Rights in BRII-179

February 14, 2024

Cooley advised Brii Biosciences on its agreements with VBI Vaccines (NASDAQ: VBIV) to ensure expansion and control of future clinical and commercial supplies of BRII-179, a late-stage clinical asset in Brii Bio’s hepatitis B virus functional cure portfolio. With operations in major biotechnology centers in the US and China, Brii Bio (HKSE: 2137) is a Hong Kong Stock Exchange-listed biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs.

Read more

Related contacts

Yiming Liu
Partner in Charge – Shanghai, Shanghai
Rama Padmanabhan
Partner, San Diego
Rajdeep Roger Bains
Associate, San Diego
Jason Savich
Partner, San Francisco
Lila Hope
Partner, Palo Alto
Michael Klein
Partner, New York
Michelle Garcia Schulman
Partner, Reston
Matthew S. Scarano
Associate, San Diego
Jameson Davis
Associate, Boston
Kaiting Yang
Associate, Hong Kong
Ross Eberly
Partner, Los Angeles Santa Monica
Jeffrey J. Tolin
Partner, New York
Michael Yu
Partner in Charge – Hong Kong, Hong Kong
Robert Eisenbach
Of Counsel, San Francisco
Rena Kaminsky
Special Counsel, Palo Alto
Olya Antle
Associate, Washington, DC
Adrienne Beaudoin Deshmukh
Associate, Reston
Yoni Horn
Associate, Los Angeles Santa Monica
Patrick Sharma
Associate, Los Angeles Santa Monica
Lunga Su
Associate, Shanghai
Yiying Wang
Associate, Shanghai

Related Practices & Industries

Allorion Therapeutics Announces Exclusive Option, Global License Agreement With AstraZeneca

January 2, 2024

Cooley advised Allorion Therapeutics, a US- and China-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune diseases, on its exclusive option and global license agreement with AstraZeneca to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor as a potential new treatment for advanced EGFR-mutant non-small-cell lung cancer.

Read more

Related contacts

Marya Postner
Partner, Palo Alto
Brendan Haberle
Associate, San Diego
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Jameson Davis
Associate, Boston
Xander Lee
Partner, Los Angeles Santa Monica
Mor Agam
Associate, New York
Sharon Connaughton
Special Counsel, Washington, DC
Rachel Thorn
Partner, New York
Elizabeth Anne Wright
Of Counsel, Brussels
Natasha Leskovsek
Of Counsel, Washington, DC
Jessica Koffel
Associate, Brussels
Robert Eisenbach
Of Counsel, San Francisco

Related Practices & Industries

ImmuneOnco Biopharmaceuticals – HK$319 Million IPO

September 5, 2023

Cooley advised ImmuneOnco Biopharmaceuticals, a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies, on its HK$319 million initial public offering.

Read more

Related contacts

Yiming Liu
Partner in Charge – Shanghai, Shanghai
Michael Yu
Partner in Charge – Hong Kong, Hong Kong
Xander Lee
Partner, Los Angeles Santa Monica
Francis Wheeler
Partner, Colorado
Eric Blanchard
Partner, Boston
Yiying Wang
Associate, Shanghai
Kaiting Yang
Associate, Hong Kong
Yunxiang Xu
Associate, Shanghai
Xiaoyu Xu
Associate, Beijing
Cecilia Bai
Associate , Singapore
Rick Jantz
Associate, Los Angeles Santa Monica
Cindy Pan
International Legal Project Manager, Hong Kong
Alex Wu
International Legal Project Manager, Shanghai
Iris Yang
Senior Legal Assistant, Shanghai
Zhengyang Li
Senior Legal Assistant, Hong Kong

Related Practices & Industries

Laekna Announces Largest 18A IPO Year to Date at HK$791 Million

June 29, 2023

Cooley advised China International Capital Corporation Hong Kong Securities Limited (CICC) and other underwriters on Laekna’s HK$791 million (US$101 million) initial public offering of 63,728,000 shares on the Hong Kong Stock Exchange, the largest 18A offering year to date.

Read more

Related contacts

Michael Yu
Partner in Charge – Hong Kong, Hong Kong
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Tonny Yu
Associate, Hong Kong
Xiaoyu Xu
Associate, Beijing
April Wang
Associate, Hong Kong
Cindy Pan
International Legal Project Manager, Hong Kong
Iris Yang
Senior Legal Assistant, Shanghai
Philip Kwan
Senior Legal Assistant, Hong Kong
Zhengyang Li
Senior Legal Assistant, Hong Kong

Related Practices & Industries

IMPACT Therapeutics Announces Global License Collaboration Agreement With Eikon

June 14, 2023

Cooley advised IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer innovative drugs based on synthetic lethality on its license and collaboration agreement with Eikon Therapeutics, a biotechnology company.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Xiaoyu Xu
Associate, Beijing
Xiaozhen (Shawn) Yu
Associate, Washington, DC
Amanda Pacheco
Associate, Palo Alto
Chen Chen
Associate, Palo Alto

Related Practices & Industries

View more

Admissions & credentials

New York

Hong Kong (Registered Foreign Lawyer)

Rankings & accolades

China Business Law Journal (CBLJ) “The A-List” elite lawyers in China - Growth Driver (2023-2024)

IFLR1000 Asia Pacific Rankings: M&A in China - Foreign Firm: Rising Star Partner (2023)

Asian Legal Business (ALB), Thomson Reuters: China Top 15 Capital Markets Lawyers (2022)

Asian Legal Business (ALB), Thomson Reuters: China Top 15 Rising Lawyers (2022)